AGIO Agios Pharmaceuticals, Inc.
USHealthcareAs of 2026-07-10 13:10
Why AGIO matters now
Agios Pharmaceuticals, Inc. (AGIO) is a US stock in Healthcare. The latest InvestLog snapshot shows $41.12 with -3.90% on the session and $2.45B in market capitalization; recent performance reads 1-month +23.19% and YTD +25.50%.
The latest financial table shown here is Q1 2026, with revenue of $20.7M, net income of $-99.1M, and EPS of $-1.69. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -18.9%.
The latest indexable market news headline is "Here's Why Shares in Novo Nordisk Rival, Agios Pharmaceutical, Soared This Week" from The Motley Fool.
Additional event context on this page matters because analyst consensus is Buy with a median target of $40.00; recent insider activity includes CAPELLO JEFFREY D filing M-Exempt; recent congressional disclosure data includes Gilbert Cisneros Purchase. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
1.81
P/S
30.76
EV/EBITDA
-4.67
DCF Value
$3.94
FCF Yield
-18.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
82.1%
Operating Margin
-720.0%
Net Margin
-639.8%
ROE
-34.1%
ROA
-35.7%
ROIC
-41.4%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $20.7M | $-99.1M | $-1.69 |
| Q4 2025 | $20.0M | $-108.0M | $-1.85 |
| FY 2025 | $54.0M | $-412.8M | $-7.12 |
| Q3 2025 | $12.9M | $-103.4M | $-1.78 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$43.33
Target (Median)
$40.00
Target Range
$36.00 - $54.00
Trading Activity
Insider Trades
Congress Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.59
Agios Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to the research and advancement of new treatments, specifically targeting cellular metabolism and related biological fields. The company's offerings include PYRUKYND (mitapivat), a medication designed to activate both wild-type and various mutated pyruvate kinase (PK) enzymes, used in the management of hemolytic anemias. Additionally, Agios is developing AG-946, which is currently undergoing Phase I clinical studies for treating hemolytic anemias and other diseases. Established in 2007, the company's main office is located in Cambridge, Massachusetts.